SignalCorporate
Tactile Medical targets $50M-$52M adjusted EBITDA in 2026 while maintaining $360M-$366M revenue outlook
Tactile Medical targets $50M-$52M adjusted EBITDA for 2026 while maintaining $360M-$366M revenue outlook.
Context
What happened: Tactile Systems Technology (TCMD) reported Q3 revenue of $91.9 million and reiterated its 2026 outlook on an earnings call.
Key numbers: Q3 revenue $91.9 million. Lymphedema revenue grew 13% year over year, the fifth consecutive quarter of double-digit growth. 2026 revenue outlook $360M to $366M. 2026 adjusted EBITDA target $50M to $52M.
Why it matters: Management kept its full-year revenue guidance while targeting adjusted EBITDA of $50M to $52M for 2026, and cited sustained above-market growth in lymphedema.
What changed
Tactile Systems Technology (TCMD) reported Q3 revenue of $91.9 million and reiterated its 2026 outlook on an earnings call.
Why it matters
Management kept its full-year revenue guidance while targeting adjusted EBITDA of $50M to $52M for 2026, and cited sustained above-market growth in lymphedema.